Drug shortage
Epoprostenol Sodium Injection · GlaxoSmithKline
FDA drug shortage · To Be Discontinued · updated Jan 31, 2025
Key facts
| Generic name | Epoprostenol Sodium Injection |
|---|---|
| Proprietary name | Flolan |
| Company | GlaxoSmithKline |
| Presentation | Flolan, Injection, .5 mg (NDC 0173-0517-00) |
| Dosage form | Injection |
| Strength | .5 mg |
| Status | To Be Discontinued |
| Therapeutic category | Cardiovascular |
| Package NDCs | 0173-0517-00 |
| First posted | Jan 31, 2025 |
| Last updated | Jan 31, 2025 |
| Discontinued | Jan 31, 2025 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: